Ava Vargason

Ava Vargason

Auto-generated profile, based on publicly available information

Ava Vargason

READDI AViDD Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
AVAva M. Vargason
Ava M. Vargason
AAAaron C. Anselmo
Aaron C. Anselmo
SMSamir Mitragotri
Samir Mitragotri

1 May 2018 in Bioengineering & Translational Medicine
Verified
Journal Article
Open access
PDF file
AVAva M. Vargason
Ava M. Vargason
AAAaron C. Anselmo
Aaron C. Anselmo
Next generation microbe‐based therapeutics, inspired by the success of fecal microbiota transplants, are being actively investigated in clinical trials to displace or eliminate pathogenic microbes to treat various diseases in the gastrointestinal tract, skin, and vagina. Genetically engineered microbes are also being investigated in the clinic as drug producing factories for biologic delivery, which can provide a constant local source of drugs. In either case, microbe‐therapeutics have the opportunity to address unmet clinical needs and open new areas of research by reducing clinical side effects associated with current treatment modalities or facilitating the delivery of biologics. This review will discuss examples of past and current clinical trials that are investigating microbe‐therapeutics, both microbiome‐modulating and drug‐producing, for the treatment of a range of diseases. We then offer a perspective on how preclinical approaches, both those focused on developing advanced delivery systems and those that use in vitro microbiome model systems to inform formulation design, will lead to the realization of next‐generation microbe‐therapeutics.

14 May 2020 in Small
Verified
Journal Article
Closed access
PDF file
AVAva M. Vargason
Ava M. Vargason
SSShruti Santhosh
Shruti Santhosh
AAAaron C. Anselmo
Aaron C. Anselmo

9 July 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
BRBose Muthu Ramalingam
Bose Muthu Ramalingam
JSJohn D. Sears
John D. Sears
KTKacey M. Talbot
Kacey M. Talbot
YSYuan-Wei Norman Su
Yuan-Wei Norman Su
SHScott Houliston
Scott Houliston
TWTimothy M Willson
Timothy M Willson
Alphaviruses are mosquito-borne RNA viruses that pose a significant public health threat, with no FDA-approved antiviral therapeutics available. The nonstructural protein 2 helicase (nsP2hel) is an enzyme involved in unwinding dsRNA essential for alphavirus replication. This study reports the discovery and optimization of first-in-class oxaspiropiperidine inhibitors targeting nsP2hel. Structure-activity relationship (SAR) studies identified potent cyclic sulfonamide analogs with nanomolar antiviral activity against chikungunya virus (CHIKV). Biochemical analyses of nsP2hel ATPase and RNA unwindase activities showed these compounds act in a noncompetitive mode, suggesting that they are allosteric inhibitors. Viral resistance mutations mapped to nsP2hel and a fluorine-labeled analog exhibited direct binding to the protein by 19F NMR. The lead inhibitor, 2o, demonstrated broad-spectrum antialphaviral activity, reducing titers of CHIKV, Mayaro virus (MAYV), and Venezuelan equine encephalitis virus (VEEV). These findings support nsP2hel as a viable target for the development of broad-spectrum, direct-acting antialphaviral drugs.

12 May 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
MHMohammad Anwar Hossain
Mohammad Anwar Hossain
AMAbigail K. Mayo
Abigail K. Mayo
AGAnirban Ghoshal
Anirban Ghoshal
STSharon Taft-Benz
Sharon Taft-Benz
EAElizabeth Jane Anderson
Elizabeth Jane Anderson
TWTimothy M Willson
Timothy M Willson
RA-0002034 (1) is a potent covalent inhibitor targeting the nsP2 cysteine protease. The species-dependent pharmacokinetics and metabolism of 1 were investigated to evaluate its therapeutic potential. Pharmacokinetic profiling revealed rapid clearance in mice, predominantly mediated by glutathione S-transferase (GST)-catalyzed conjugation. This metabolic liability contrasted with slower clearance observed in human hepatocytes and preclinical species, such as rats, dogs, and monkeys. Cross-species studies confirmed the dominance of GST-driven metabolism in mice, whereas oxidative pathways were more pronounced in dogs. Despite rapid systemic clearance, 1 achieved antiviral efficacy in mice, reducing chikungunya (CHIKV) viral loads in multiple tissues. These cross-species pharmacokinetic and metabolism studies support the continued evaluation of 1 as a potential antialphaviral therapeutic to further define the contribution of hepatic and non-hepatic GST metabolism to its clearance in humans.

18 July 2025 in ACS Infectious Diseases
Verified
Journal Article
Open access
BRBose Muthu Ramalingam
Bose Muthu Ramalingam
HOHans J. Oh
Hans J. Oh
JSJohn D. Sears
John D. Sears
CCChun-Hsing Chen
Chun-Hsing Chen
AVAnand Vala
Anand Vala
TWTimothy M Willson
Timothy M Willson
Chikungunya virus (CHIKV) replication relies on the multifunctional nsP2 protein, making it an attractive target for antiviral drug discovery. Here, we report the resolution of oxaspiropiperidine 1, a first-in-class inhibitor of the CHIKV nsP2 RNA helicase (nsP2hel), into its constitutive enantiomers and characterization of their antiviral activity. The enantiomer (R)-1 exhibited potent inhibition of viral replication, nsP2hel ATPase activity, and dsRNA unwinding, while the (S)-1 enantiomer was >100-fold less active. The (R)-1 enantiomer also demonstrated a high selectivity for CHIKV over other RNA viruses and for nsP2hel over other RNA helicases. Direct binding of (R)-1 to the nsP2hel protein was confirmed by 19F NMR. Biophysical and structural studies revealed conformational polymorphism in the spirocyclic scaffold of (R)-1, suggesting a potential role of thermal mobility of the ligand in allosteric inhibition of nsP2hel. Collectively, these findings designate (R)-1 (RA-NSP2-1) as a high-quality chemical probe and (S)-1 (RA-NSP2-1N) as a negative control for probing the biology of alphavirus RNA helicases.